ConvaTec Group Plc (CNVVY) Stock Price & Analysis
ConvaTec Group Plc (CNVVY) — price $11.62 (+0.66%), as of the Oct 5, 2026 trading session; market cap $5.68B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 57.37× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Feb 23, 2027
ConvaTec Group Plc · CNVVY · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: ConvaTec develops and distributes medical devices for wound care, ostomy management, continence solutions, and hospital critical care across more than a hundred countries. The company's financial case turns on whether persistent debt can be serviced while the business matures into steady profitability.
Price as of Oct 5, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $11.62 | |
| Change on the day | +0.66% | |
| 52-week range | $10.45 – $14.09 | |
| Market capitalisation | $5.68B | |
| Price / earnings (trailing) | 45.36 | |
| Shares traded on the day | 2K | |
| Beta (volatility vs the S&P 500) | 0.84 | |
| Dividends per share (last 12 months) | $0.30 | |
| Dividend yield (last 12 months) | 2.61% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
On operating margin, we continue to expect to reach at least 23%, inclusive of InnovaMatrix headwinds of about 80 basis points for the full year, and FX headwinds of about 40 basis points.
Fiona Ryder · Statement from
We expect working capital flow to reverse in the second half as it does each year.
Fiona Ryder · Statement from
Chronological order, not a duration scale. Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for ConvaTec Group (CNVVY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Oct 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the CNVVY film — every key number, told as a short cinematic story
~2 min · open the film
What is ConvaTec Group (CNVVY), and what does it report?
Short answer · as of
ConvaTec manufactures and distributes medical devices across four main categories: advanced wound-care products for acute and chronic wounds; ostomy care systems for patients with colostomies or ileostomies; continence solutions including intermittent catheters; and critical-care supplies for intensive-care units.
Research dated 2026-09-13.
ConvaTec manufactures and distributes medical devices across four main categories: advanced wound-care products for acute and chronic wounds; ostomy care systems for patients with colostomies or ileostomies; continence solutions including intermittent catheters; and critical-care supplies for intensive-care units. Customers include hospitals, healthcare providers, and patients who purchase through direct channels, distributors, and wholesalers.
The reported financial statements measure manufacturing throughput, sales mix, and gross-margin realization. Operating results reflect the spread between product cost and selling price, after deducting research, commercial expenses, and administrative overhead.
What do the latest results show for ConvaTec Group (CNVVY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.23B.
Research dated 2026-09-13.
The most recent quarter showed revenue and earnings per share both declined from the prior-year period, though the decline in reported earnings was steeper than the top-line contraction. Gross profit held as a percentage of revenue, indicating the margin pressure came from higher operating expenses rather than manufacturing cost inflation.
Management cited certain product transitions and integration headwinds as temporary factors, with a clear statement that operating margin should reach acceptable levels in the full year.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.23B Jun 30, 2026
- Latest quarter · R&D
- $61.99M Jun 30, 2026
- Latest quarter · SG&A
- $427.92M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $178.97M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $1.23B | $61.99M | $427.92M | $178.97M |
| Dec 31, 2025 | $1.25B | $59.28M | $450.90M | $224.26M |
| Jun 30, 2025 | $1.18B | $53.50M | $423.10M | $179.20M |
| Dec 31, 2024 | $1.18B | $55.53M | $401.42M | $183.34M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.23B Aug 4, 2026
- Latest report · revenue estimate
- $1.23B Aug 4, 2026
- Latest report · revenue vs estimate
- In line Aug 4, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $1.23B | $1.23B | $0.1100 | $0.3312 |
| Feb 24, 2026 | $1.26B | $1.25B | $0.3872 | $0.4000 |
| Jul 29, 2025 | $1.18B | $1.17B | $0.3200 | $0.3146 |
| Feb 26, 2025 | $1.18B | $1.18B | $0.3376 | $0.3200 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.23B | $54M | $0.11 (diluted) |
| Q4 FY2025 | $1.25B | $70M | $0.14 (diluted) |
| Q2 FY2025 | $1.18B | $105M | $0.20 (diluted) |
| Q4 FY2024 | $1.18B | $111M | $0.22 (diluted) |
What are the financial strengths and risks for ConvaTec Group (CNVVY)?
Short answer
Cash and short-term investments were $99.00M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $71.99M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash generation has been robust, though it fluctuates seasonally with working capital movements. The balance sheet carries significant debt relative to annual revenue and market value, with cash holdings covering only a fraction of total obligations. The company has sufficient liquidity to meet near-term needs, but leverage remains elevated.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Rich valuation — a P/E of 45.36 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $71.99M Jun 30, 2026
- Previous quarter · operating cash flow
- $311.50M Dec 31, 2025
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $71.99M | −$127.98M |
| Dec 31, 2025 | $311.50M | −$65.00M |
| Jun 30, 2025 | $155.00M | −$56.60M |
| Dec 31, 2024 | $319.31M | −$70.27M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at ConvaTec Group (CNVVY)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027.
Research dated 2026-09-13.
Watch whether the second half achieves the indicated margin recovery. Watch working capital: the company expects a seasonal reversal of cash outflows in the latter months. Watch free-cash-flow conversion to confirm management's expectation of near-total conversion to equity holders. Watch currency effects—management noted meaningful headwinds that may reverse if the dollar weakens.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
On operating margin, we continue to expect to reach at least 23%, inclusive of InnovaMatrix headwinds of about 80 basis points for the full year, and FX headwinds of about 40 basis points.
Fiona Ryder ·
We expect working capital flow to reverse in the second half as it does each year.
Fiona Ryder ·
And as such, we continue to expect around about 100% free cash flow to equity conversion in full year '26.
Fiona Ryder ·
We are confirming our guidance for full year '26, and here's a summary to help you model.
Fiona Ryder ·
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is ConvaTec Group scored?
Research dated 2026-09-13.
ConvaTec's footprint spans specialty healthcare (wound care, ostomy) rather than broad hospital supply or home health. Compared to diversified medical-device distributors, it holds a narrower product portfolio but deeper expertise in its chosen segments. Geographic presence covers developed markets primarily, with growing presence in emerging markets but less penetration than some larger competitors.
| Company | Price | Market value | Score |
|---|---|---|---|
| $12.87 Oct 5, 2026 | $6.36B | — Model unavailable | |
| $4.16 Oct 5, 2026 | $7.37B | — Model unavailable | |
| $24.90 Oct 5, 2026 | $6.78B | — Model unavailable | |
| $7.08 Oct 5, 2026 | $5.25B | — Model unavailable | |
| $11.60 Oct 5, 2026 | $7.17B | — Model unavailable | |
| $125.24 Oct 5, 2026 | $5.49B | — 5-pillar · not comparable | |
| $20.05 Oct 5, 2026 | $5.47B | — 5-pillar · not comparable | |
| $17.17 Oct 5, 2026 | $6.13B | — 5-pillar · not comparable | |
| $87.14 Oct 5, 2026 | $5.20B | — 5-pillar · not comparable | |
| $104.68 Oct 5, 2026 | $4.76B | — 5-pillar · not comparable | |
| $120.61 Oct 5, 2026 | $7.59B | — 5-pillar · not comparable | |
| $161.40 Oct 5, 2026 | $4.03B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about ConvaTec Group (CNVVY)?
CNVVY Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
Why does ConvaTec maintain such high debt levels?
The debt likely reflects prior acquisition strategy or dividend payouts. At current operating cash flows, the debt is serviceable but constrains financial flexibility for additional shareholder distributions.
What happens if hospital budgets contract or insurance coverage for ostomy products tightens?
Both risks would reduce unit volumes and push the company toward lower-margin channels or forced price concessions. The revenue mix already depends heavily on hospital and pharmacy purchasing decisions.
Is dividend income reliable from this company?
Dividends have been paid consistently, but they remain modest relative to earnings. Continued debt service takes priority; further increases are unlikely until leverage improves.
Where is most of the company's revenue coming from geographically?
The brief does not detail geographic revenue splits, only that distribution spans multiple countries and regions. Hospital and healthcare-provider concentration suggests developed-market weighting.
What is the CNVVY stock price today?
The last price recorded on this page for ConvaTec Group Plc (CNVVY) is $11.62, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (68 figures)
The 68 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Fiona Ryder (Aug 4, 2026): On operating margin, we continue to expect to reach at least 23%, inclusive of InnovaMatrix headwinds of about 80 basis points for the full year, and FX headwinds of about 40 basis points. Fiona Ryder (Aug 4, 2026): We expect working capital flow to reverse in the second half as it does each year. Fiona Ryder (Aug 4, 2026): And as such, we continue to expect around about 100% free cash flow to equity conversion in full year '26. Fiona Ryder (Aug 4, 2026): We are confirming our guidance for full year '26, and here's a summary to help you model. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 60 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Feb 23, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $11.62 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T18:20:32.000Z. | |
px.change | Change on the day | +0.66% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.68B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T18:20:32.000Z. Captured from FMP at 2026-10-05T18:37:08.319Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.0757 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 45.36 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.84 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Jonathan Peter Mason | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 10,910 | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | 20 Eastbourne Terrace, London, GL, W2 6LG, GB | FMP | Financial Modeling Prep (FMP) company profile — The FMP company description names Reading, United Kingdom as the headquarters; this page uses the address in this row. | |
fin.q_revenue | Revenue, Q2 FY2026 | $1.23B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $2.04B, net result $117.60M; FY2022 revenue $2.07B, net result $62.90M; FY2023 revenue $2.14B, net result $130.30M; FY2024 revenue $2.29B, net result $190.50M; FY2025 revenue $2.44B, net result $175.41M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 55.1% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $1.23B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $61.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $427.92M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $178.97M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $1.25B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $59.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $450.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $224.26M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.revenue_k | Revenue — period end 2025-06-30 | $1.18B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.rd_k | R&D — period end 2025-06-30 | $53.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.sga_k | SG&A — period end 2025-06-30 | $423.10M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.operating_result_k | FMP standardized operating result — period end 2025-06-30 | $179.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.revenue_k | Revenue — period end 2024-12-31 | $1.18B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.rd_k | R&D — period end 2024-12-31 | $55.53M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.sga_k | SG&A — period end 2024-12-31 | $401.42M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.operating_result_k | FMP standardized operating result — period end 2024-12-31 | $183.34M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $1.23B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $1.23B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | $0.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | $0.3312 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_actual | Revenue · reported — report date 2026-02-24 | $1.26B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_estimated | Revenue · estimate — report date 2026-02-24 | $1.25B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_actual | EPS · reported — report date 2026-02-24 | $0.3872 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_estimated | EPS · estimate — report date 2026-02-24 | $0.4000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-29.revenue_actual | Revenue · reported — report date 2025-07-29 | $1.18B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-29.revenue_estimated | Revenue · estimate — report date 2025-07-29 | $1.17B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-29.eps_actual | EPS · reported — report date 2025-07-29 | $0.3200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-29.eps_estimated | EPS · estimate — report date 2025-07-29 | $0.3146 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-26.revenue_actual | Revenue · reported — report date 2025-02-26 | $1.18B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-26.revenue_estimated | Revenue · estimate — report date 2025-02-26 | $1.18B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-26.eps_actual | EPS · reported — report date 2025-02-26 | $0.3376 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-26.eps_estimated | EPS · estimate — report date 2025-02-26 | $0.3200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $99.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $71.99M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $42.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $1.74B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.89× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $71.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $311.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$127.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$65.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.operating_cash_flow_m | Operating cash flow — period end 2025-06-30 | $155.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.capex_m | Capital expenditure (reported) — period end 2025-06-30 | −$56.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.operating_cash_flow_m | Operating cash flow — period end 2024-12-31 | $319.31M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.capex_m | Capital expenditure (reported) — period end 2024-12-31 | −$70.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $10.45 – $14.09 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 57.37× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $99.00M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.30 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.61% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | In line | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.23B) with the recorded estimate ($1.23B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1100) with the recorded estimate ($0.3312) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-06-30.revenue_k,fin.q_table.depth.2025-06-30.rd_k,fin.q_table.depth.2025-06-30.sga_k,fin.q_table.depth.2025-06-30.operating_result_k,fin.q_table.depth.2024-12-31.revenue_k,fin.q_table.depth.2024-12-31.rd_k,fin.q_table.depth.2024-12-31.sga_k,fin.q_table.depth.2024-12-31.operating_result_k. - Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-02-24.revenue_actual,earn.history.depth.2026-02-24.revenue_estimated,earn.history.depth.2026-02-24.eps_actual,earn.history.depth.2026-02-24.eps_estimated,earn.history.depth.2025-07-29.revenue_actual,earn.history.depth.2025-07-29.revenue_estimated,earn.history.depth.2025-07-29.eps_actual,earn.history.depth.2025-07-29.eps_estimated,earn.history.depth.2025-02-26.revenue_actual,earn.history.depth.2025-02-26.revenue_estimated,earn.history.depth.2025-02-26.eps_actual,earn.history.depth.2025-02-26.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-06-30.operating_cash_flow_m,fin.opcf.depth.2025-06-30.capex_m,fin.opcf.depth.2024-12-31.operating_cash_flow_m,fin.opcf.depth.2024-12-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | ConvaTec Group Plc | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | ConvaTec Group Plc operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a wide range of healthcare products. The company offers advanced wound care and skin protection solutions, tailored for the effective management of both acute and chronic wounds arising from diverse conditions such as diabetes, immobility, venous disease, traumatic injuries, burns, or complications following surgery. Furthermore, ConvaTec provides comprehensive ostomy care, including specialized devices, accessories, and support services for individuals living with a stoma, often necessitated by conditions like colorectal or bladder cancer, inflammatory bowel disease, obesity, among other medical reasons. Its product portfolio also extends to continence and critical care. This encompasses intermittent urinary catheters and solutions for managing bladder control issues linked to spinal cord injuries, multiple sclerosis, spina bifida, and various other urological disorders. Additionally, the firm supplies medical devices and products specifically designed for use in intensive care units (ICUs) and broader hospital settings. ConvaTec develops sophisticated systems for handling acute fecal incontinence, as well as for precise monitoring of urine production output and intra-abdominal pressure. A diverse array of disposable medical devices is also provided, featuring wound drainage systems, urine collection bags and catheters, equipment for airway management and oxygen/aerosol therapy, suction handles and tubing, gastroenterology tubes, and securement devices. The company is also a supplier of disposable infusion sets to manufacturers of insulin pumps for diabetic patients, and similar sets for pumps employed in continuous infusion treatments for other medical conditions. ConvaTec serves a broad spectrum of clients, including healthcare providers, patients, and other manufacturers. Its products reach both hospital and home healthcare markets, distributed through direct sales, as well as via distributors and wholesalers, targeting pharmacies, hospitals, and various acute and post-acute healthcare service providers. Established in 1978, the company's corporate headquarters are located in Reading, United Kingdom. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$1.64B; Total debt: $1.74B; Cash and investments: $99.00M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-04 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $1.74B; Liquidity basis: cash and short-term investments; Total liabilities: $2.36B; Cash and short-term investments: $99.00M; Cash and investments: $141.00M; Long-term investments: $42.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Cash decline over the reported window | To: 2026-06-30; From: 2022-12-31; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $99.00M; Decline: $44.80M; Opening balance: $143.80M; Average change per period: $6.40M Change in cash, cash equivalents and short-term investments between the 2022-12-31 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-04 | FMP | Financial Modeling Prep (FMP) earnings |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-08-21 | FMP | Financial Modeling Prep (FMP) dividend history |
| Trailing twelve-month ratio set | Quick ratio: 1.09; Current ratio: 1.93; Debt to equity: 1.22; Net margin: 5%; Gross margin: 55.1%; Operating margin: 16.2%; Return on assets: 3.3%; Return on equity: 8.4% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
Data provided for informational purposes only.